Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Chemomab Therapeutics (Nasdaq: CMMB) said CEO Dr. Adi Mor and senior management will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 8:00 am ET.
The corporate presentation will be webcast live and available on the company's investor relations website for 90 days; management will also hold one-on-one investor meetings.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Phase 2 data | Positive | -3.4% | Publication of nebokitug Phase 2 SPRING PSC results in major journal. |
| Nov 24 | Investor conference | Neutral | -4.7% | Participation at Oppenheimer rare disease summit with investor meetings. |
| Nov 20 | Quarterly earnings | Positive | -10.0% | Q3 2025 results and regulatory alignment on single Phase 3 trial. |
| Nov 06 | Clinical presentations | Positive | -3.4% | AASLD liver meeting posters with favorable nebokitug OLE data. |
| Aug 21 | Investor conference | Neutral | -3.6% | Announcement of H.C. Wainwright global investment conference participation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows a pattern of negative price reactions after fundamentally positive clinical and earnings updates, while neutral conference appearances have seen smaller, more typical declines.
Over the last six months, Chemomab has focused updates on nebokitug’s Phase 2 SPRING data and investor outreach. Positive clinical publications and AASLD presentations in Nov–Dec 2025 and a Q3 2025-11-20 earnings/update all saw share price declines of 3–10% the next day, indicating a tendency for weakness after good news. Prior conference-related announcements, such as the H.C. Wainwright event on Aug 21 and Oppenheimer’s rare disease summit on Nov 24, also coincided with modest pullbacks, providing context for another non-clinical conference appearance today.
Key Terms
fibro-inflammatory medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The corporate presentation will be webcast live and will be available at the investor relations section of the Chemomab website for 90 days.
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | |
| Date: | February 26, 2026 |
| Time: | 8:00 am ET |
| Venue: | Virtual |
| Format: | Webcast presentation |
| Webcast Link: | https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/L6ucs8kK8ypQvdjEBzP3QH |
| Information: | opcoconferences@opco.com |
About Chemomab Therapeutics Ltd. .
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from five clinical trials of nebokitug. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), Chemomab and the FDA have aligned on the design of a nebokitug Phase 3 registration trial in patients with PSC. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s nebokitug program for the treatment of systemic sclerosis has received FDA and EMA Orphan Drug designations and has an open U.S. IND. For more information, visit: chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
